Literature DB >> 17512087

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

Joseph Jorizzo1, Scott Dinehart, Robert Matheson, Jeffrey K Moore, Mark Ling, Terry L Fox, Scott McRae, Sandra Fielder, James H Lee.   

Abstract

BACKGROUND: A shorter dosing regimen of imiquimod for the treatment of actinic keratosis may be effective, with long-term clinical benefits.
OBJECTIVE: Imiquimod in one or two shorter courses of treatment was evaluated.
METHODS: Patients with actinic keratosis lesions on the head applied imiquimod or vehicle cream 3x/wk for 4 weeks (course 1). Patients with remaining lesions received another course of treatment. Complete and partial clearance rates were evaluated after course 1, after course 2 (overall), and 1 year later.
RESULTS: Complete clearance rates were 26.8% (course 1) and 53.7% (overall). Partial clearance rates were 36.6% (course 1) and 61.0% (overall). One-year follow-up recurrence rates were 39% (imiquimod) and 57% (vehicle). LIMITATIONS: Blinded investigators may have been biased toward patients treated with imiquimod identified by treatment site reactions.
CONCLUSION: Imiquimod 3x/wk in one or two courses of treatment appears to be effective for the treatment of actinic keratoses on the head, providing long-term clinical benefits. Some recurrences do occur, so long-term follow-up is recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512087     DOI: 10.1016/j.jaad.2007.01.047

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

1.  Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.

Authors:  James Q Del Rosso; Howard Sofen; Barry Leshin; Tc Meng; James Kulp; Sharon Levy
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

2.  Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.

Authors:  C Ulrich; J Bichel; S Euvrard; B Guidi; C M Proby; P C M van de Kerkhof; P Amerio; J Rønnevig; H B Slade; E Stockfleth
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

Review 3.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Imiquimod 2.5% and 3.75% Cream for the Treatment of Photodamage: A Meta-analysis of Efficacy and Tolerability in 969 Randomized Patients.

Authors:  James Del Rosso; Neil Swanson; Brian Berman; George M Martin; Tina Lin; Ted Rosen
Journal:  J Clin Aesthet Dermatol       Date:  2018-09-01

Review 5.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.

Authors:  Keith Tolley; Danny Kemmett; Signe Thybo; Ruth Nasr; Helen Smethurst
Journal:  Eur J Health Econ       Date:  2015-03-21

7.  Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study.

Authors:  Dow Stough; Alicia D Bucko; George Vamvakias; Elyse S Rafal; Steven A Davis
Journal:  J Clin Aesthet Dermatol       Date:  2008-07

Review 9.  [Skin tumours of the facial area].

Authors:  M Braun-Falco
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

10.  Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.

Authors:  Ralf Gutzmer; Susanne Wiegand; Oliver Kölbl; Kai Wermker; Markus Heppt; Carola Berking
Journal:  Dtsch Arztebl Int       Date:  2019-09-13       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.